Results for the Combination of Ublituximab and Ibrutinib in CLL

July 7, 2017
Jeff Sharman, MD

Jeff Sharman, MD, discusses findings of the phase III GENUINE study, which explored the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).